Merus’ Petosemtamab Monotherapy Interim Knowledge Continues to Show Clinically Significant Exercise in 2L+ r/m HNSCC By Investing.com
Petosemtamab together with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with…
Novartis oral Fabhalta ® (iptacopan) sustained clinically significant outcomes at one yr in Section III C3 glomerulopathy (C3G) trial By Investing.com
New APPEAR-C3G knowledge present Fabhalta sustained proteinuria discount at 12 months1Upon Fabhalta…
